T-lymphocyte activation antigen CD86
| GO Term | Evidence Code | Reference |
|---|---|---|
| adaptive immune response |
|
|
| positive regulation of immunoglobulin production | ||
| immune response | ||
| immune response | ||
| cell surface receptor signaling pathway |
| GO Term | Evidence Code | Reference |
|---|---|---|
| plasma membrane | ||
| plasma membrane | ||
| plasma membrane | ||
| plasma membrane | ||
| plasma membrane |
| GO Term | Evidence Code | Reference |
|---|---|---|
| virus receptor activity |
|
|
| coreceptor activity | ||
| signaling receptor activity | ||
| receptor ligand activity |
| Position | Description | PubMed ID | GlyTouCan ID | Source |
|---|---|---|---|---|
| 33 |
|
|
||
| 47 |
|
|
||
| 135 |
|
|
||
| 146 |
|
|
||
| 154 |
|
|
||
| 177 |
|
|
||
| 192 |
|
|
||
| 213 |
|
|
| Pathway Name | Organism |
|---|---|
| CD28 co-stimulation | Homo sapiens |
| CD28 dependent PI3K/Akt signaling | Homo sapiens |
| CD28 dependent Vav1 pathway | Homo sapiens |
| Co-inhibition by CTLA4 | Homo sapiens |
| Constitutive Signaling by Aberrant PI3K in Cancer | Homo sapiens |
| Interleukin-10 signaling | Homo sapiens |
| PI3K/AKT Signaling | Homo sapiens |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | Homo sapiens |
Tissue with high expression from Human Protein Atlas. Tissues that are highly expressed are highlighted.
| DO ID | Disease Name | Source |
|---|---|---|
| DOID:11123 | IgA vasculitis | |
| DOID:1040 | chronic lymphocytic leukemia | |
| DOID:9744 | type 1 diabetes mellitus | |
| DOID:2377 | multiple sclerosis | |
| DOID:418 | systemic scleroderma | |
| DOID:2841 | asthma | |
| DOID:8924 | autoimmune thrombocytopenic purpura | |
| DOID:3083 | chronic obstructive pulmonary disease |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.5.0
Last updated: April 6, 2026